Related coverage linked through entity extraction aliases.
Apr 18, 2026
GLP-1 drugs are expanding in 2026 with oral semaglutide for weight management, rising patient use and broader commercialization. A study also found a modest increase in erectile dysfunction risk among men with Type 2 diabetes starting GLP-1 medicines, though the association weakened after stricter adjustment.
Apr 17, 2026
Europe's infusion pump market is projected to reach USD 7.09 billion by 2031 at a 6.8% CAGR. Growth is driven by connected systems, tighter safety standards, homecare use, and diabetes demand.
Apr 14, 2026
Samsung Bioepis plans to start a global Phase 1 trial of SBE303, its first independently developed new drug candidate targeting Nectin-4. Preclinical data showed tolerability up to 40 mg/kg in monkeys.
Apr 12, 2026
The global API market is projected to grow to USD 198.39 billion by 2030 from USD 144.20 billion in 2025, at a 6.6% CAGR. Oncology, rare disease and diabetes pipelines are key growth drivers.
Apr 11, 2026
Q1 2026 sleep medicine trends include broader use of AI, expanding obstructive sleep apnea and narcolepsy treatments, and policy changes affecting reimbursement and access.
Apr 08, 2026
Updated pediatric hypertriglyceridemia guidance says triglyceride thresholds below 400 mg/dL mainly signal ASCVD risk, while levels above about 885 mg/dL raise pancreatitis risk. Lifestyle changes remain first-line treatment, and pediatric-specific evidence for drug therapy is still limited.
Apr 08, 2026
The FDA has approved icotrokinra, the first oral IL-23 therapy for moderate-to-severe plaque psoriasis. Meanwhile, real-world research shows IL-23 inhibitors produce site-specific responses in high-impact areas like scalp and nails, and combination therapy with ixekizumab and tirzepatide shows superior results for psoriasis patients with obesity.
Apr 08, 2026
Researchers have used a machine learning model called AI-IR to demonstrate that insulin resistance is a risk factor for 12 types of cancer. The tool analyzes nine clinical parameters from standard health checkups to predict insulin resistance at population scale. This provides the first large-scale evidence linking insulin resistance to multiple cancers.
Apr 06, 2026
Doctors said Americans starting obesity treatment are showing interest in oral GLP-1 drugs because of lower cost and convenience. Novo’s oral Wegovy and Lilly’s Foundayo are priced below injectable options.
Apr 04, 2026
Large-cap healthcare stocks such as Johnson & Johnson and CVS Health are viewed as defensive in a slowdown, with beta values of 0.33 and 0.46. Investors can also pursue higher-risk healthcare companies such as Grail and Viking Therapeutics, whose performance depends more on clinical and product milestones.
Apr 03, 2026
President Trump imposes 100% tariffs on imported branded drugs from companies refusing price cuts or U.S. production moves. Sixteen major pharmaceutical firms have secured tariff exemptions by agreeing to align U.S. prices with other developed nations and invest in domestic manufacturing. The policy aims to reduce prescription drug costs and rebuild domestic pharmaceutical production capacity.
Apr 02, 2026
Pharmaceutical M&A is shifting toward late-stage clinical assets with proven human data, particularly in GLP-1 obesity drugs, oncology, and central nervous system disorders. Companies like Viking Therapeutics, Structure Therapeutics, and Revolution Medicines represent compelling acquisition targets with advanced clinical programs. This trend reflects industry prioritization of de-risked assets that can accelerate commercialization pathways.
Apr 01, 2026
The FDA has shifted from regulatory ambiguity to coordinated enforcement against compounded oral semaglutide, culminating in a 2026 announcement of intent to take action against non-approved GLP-1 drugs. Hims & Hers Health's 2024 oral semaglutide offering marked the beginning of a broader regulatory reckoning that saw manufacturer pressure, formal shortage declarations, and warning letters targeting compounding practices.
Apr 01, 2026
The FDA has approved Eli Lilly's GLP-1 weight loss pill Foundayo, which will compete with Novo Nordisk's Wegovy pill. Foundayo will be available through LillyDirect and pharmacies, with prices ranging from $25 with insurance to $149-$349 for cash payers. The approval sets up a new battle in the oral GLP-1 market between the two pharmaceutical giants.
Apr 01, 2026
A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
Apr 01, 2026
The TrumpRx prescription discount website launched in February 2026 offers coupons for 43 brand-name drugs but has limited usefulness for most patients. Experts found 18 drugs are cheaper through other discount services, and the website doesn't indicate when generic alternatives exist. The program links to broader tariff and pricing policies affecting pharmaceutical companies.
Mar 31, 2026
Multiple Indian pharmaceutical companies including Zydus, Glenmark, Dr. Reddy's, and Alkem have launched semaglutide versions following patent expiry, dramatically reducing prices and expanding access. Companies are competing on both price and innovative delivery systems, with monthly therapy costs now ranging from Rs 1,300 to Rs 4,200. This development could significantly impact diabetes and obesity treatment in India, where over 100 million people live with diabetes.
Mar 30, 2026
Roche Holding AG shares show potential undervaluation despite strong returns, with DCF models suggesting 59% upside. The pharmaceutical giant trades at P/E ratios below fair value estimates while maintaining solid financial performance and dividend growth. Recent pipeline developments and product innovations support long-term growth prospects.
Mar 26, 2026
The European Union has approved a higher 7.2 mg maintenance dose for Wegovy (semaglutide) for chronic weight management. Clinical trial data shows mean weight loss of 20-21% with the 7.2 mg dose compared to 17-18% with the standard 2.4 mg dose. The approval provides clinicians with an on-label option for patients with inadequate response to standard dosing.
Mar 26, 2026
Eli Lilly has acquired rights to CSL's IL-6 inhibitor clazakizumab in a $100 million deal, expanding its cardiometabolic pipeline. The monoclonal antibody targets chronic inflammation, particularly in cardiovascular conditions. This move follows Lilly's successful obesity and diabetes drugs that drove $65.1 billion in 2025 revenue.
